10-Q: TNF Pharmaceuticals Amends Warrants, Reports Q2 Financials

TNF Pharmaceuticals amended warrants related to recent preferred stock offerings and reported a net loss of $19.3 million for the first half of 2024.

Summary

• TNF Pharmaceuticals amended the terms of warrants associated with its Series F-1 and Series G convertible preferred stock offerings, effective June 30, 2024.
• The amendments relate to the calculation of the Black Scholes Value of the warrants in the event of a fundamental transaction, ensuring warrant holders receive equivalent consideration to common stockholders.
• The company reported a net loss of $19.3 million for the six months ended June 30, 2024, and a net loss of $9.5 million for the three months ended June 30, 2024.
• The company's cash position was $536,026 with marketable securities of $12.5 million as of June 30, 2024.
• The company has working capital of $8.5 million and a stockholders equity of $97,805 as of June 30, 2024.
• The company's operating expenses were $6.1 million for the six months ended June 30, 2024, and $3.3 million for the three months ended June 30, 2024.
• The company issued 5,050 shares of Series F-1 Convertible Preferred Stock and 8,950 shares of Series G Convertible Preferred Stock during the period.
• The company reclassified $7.9 million of Series F warrant liabilities to equity due to a modification of the warrant terms.
• The company's research and development expenses were $1.6 million for the six months ended June 30, 2024, and $401,104 for the three months ended June 30, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has secured funding and made some positive adjustments to its balance sheet, the significant net loss and low cash position raise concerns. The company's future is heavily reliant on successful clinical trials and further capital raises.

Positives

• The company successfully raised capital through the issuance of Series F-1 and Series G preferred stock.
• The company has a significant amount of marketable securities, totaling $12.5 million.
• The company reclassified $7.9 million of Series F warrant liabilities to equity, improving the balance sheet.

Negatives

• The company reported a substantial net loss of $19.3 million for the first half of 2024.
• The company's cash position is relatively low at $536,026.
• The company's accumulated deficit is $123.3 million.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• The company's ability to settle conversions and make amortization and dividend payments using shares of Common Stock is subject to certain limitations.
• The company's ability to achieve profitability is dependent on the successful development and commercialization of its product candidates.
• The company is subject to certain restrictive covenants that may make it difficult to procure additional financing.
• The company's intellectual property rights may not be adequately protected or enforced.

Future Outlook

The company believes its current financial resources are sufficient to fund its operating budget and contractual obligations for the next twelve months. The company anticipates that its expenses will increase significantly as it advances the development of its product candidates and establishes commercialization capabilities.

Management Comments

• Management believes that the company's current financial resources are sufficient to fund its current operating budget and contractual obligations as of June 30, 2024 as they fall due within the next twelve-month period.
• Management is seeking appropriate speaking opportunities to present the company.
• Management is exploring non-dilutive opportunities to evaluate MYMD-1 in additional indications not previously considered.

Industry Context

The company is operating in the biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant competition. The company's focus on developing treatments for age-related illnesses and autoimmune diseases aligns with current trends in the pharmaceutical industry.

Comparison to Industry Standards

• The company's financial results are not directly comparable to established pharmaceutical companies with revenue-generating products.
• The company's high operating expenses and net losses are typical for early-stage biotechnology companies focused on research and development.
• The company's reliance on private placements for funding is common among pre-revenue biotech companies.
• The company's reclassification of warrant liabilities to equity is a positive step, but the overall financial position remains challenging.
• The company's cash burn rate is high, and it will need to raise additional capital to continue operations.

Management Changes

Legal Proceedings

• The company is involved in ongoing litigation with Raymond Akers, with the Second Raymond Akers Action currently in the discovery phase.

Related Party Transactions

• The company has royalty agreements with SRQ Patent Holdings and SRQ Patent Holdings II, affiliates of Mr. Jonnie Williams, Sr.
• The company has a license agreement with MIRA Pharmaceuticals, Inc., where the company's former President and Chief Medical Officer, Chris Chapman, M.D., is Executive Chairman.
• The company issued Series G Preferred Stock to PharmaCyte Biotech, Inc., where the company's Chairman of the Board, Joshua Silverman, is the interim CEO, President and Director.

Stakeholder Impact

• Shareholders face potential dilution from the issuance of new shares.
• Employees may be affected by cost-cutting measures and changes in management.
• Customers and patients may benefit from the development of new treatments.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company will continue to advance the development of MYMD-1 and Supera-CBD.
• The company will seek regulatory approvals for its product candidates.
• The company will establish commercialization capabilities to support product sales.
• The company will explore non-dilutive opportunities to evaluate MYMD-1 in additional indications.

Key Dates

Keywords

warrants, convertible preferred stock, financial results, amendment, Black Scholes Value, Series F-1, Series G, net loss, capital raise, TNF Pharmaceuticals